Genentech's Dribble (DNA)
by Jon C. Ogg
24/7 Wall St.
Genentech (DNA) posted $0.73 EPS vs $0.72 estimates, but revenues were $2.95 Billion versus a $2.93 Billion estimate. It looks like 3 of the 4 major drugs came in under expectations, with Avastin being the only above-plan seller. Here was our preview ahead of earnings.
U.S. product sales were $2.155 Billion, an 18% increase year over year. As far as guidance, Genentech continues to expect 28% to 32% growth in non-GAAP earnings per share for the full year 2007, relative to 2006, for a range of $2.85 to $2.95. unfortunatel, and at least for the time being, the street has paid much closer attention to those revenue figures.
Shares closed up 0.3% in normal trading, but shares traded down about 2% at $76.00 in the initital after-hours trading reaction before recovering a bit of the losses. Until the company clarifies its sales and expectations and until it gives more formal guidance in the conference call, this one should only be considered a partially-known earnings report.
Continue reading article at 24/7 Wall St.
24/7 Wall St. is a regular contributor to BioHealth Investor
________________
24/7 Wall St.
Genentech (DNA) posted $0.73 EPS vs $0.72 estimates, but revenues were $2.95 Billion versus a $2.93 Billion estimate. It looks like 3 of the 4 major drugs came in under expectations, with Avastin being the only above-plan seller. Here was our preview ahead of earnings.
U.S. product sales were $2.155 Billion, an 18% increase year over year. As far as guidance, Genentech continues to expect 28% to 32% growth in non-GAAP earnings per share for the full year 2007, relative to 2006, for a range of $2.85 to $2.95. unfortunatel, and at least for the time being, the street has paid much closer attention to those revenue figures.
Shares closed up 0.3% in normal trading, but shares traded down about 2% at $76.00 in the initital after-hours trading reaction before recovering a bit of the losses. Until the company clarifies its sales and expectations and until it gives more formal guidance in the conference call, this one should only be considered a partially-known earnings report.
Continue reading article at 24/7 Wall St.
24/7 Wall St. is a regular contributor to BioHealth Investor
________________
posted by Nico at
4:21 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home